Vaccine Design and Testing – News and Features

There is currently extensive literature on the use of targeted antibodies for the treatment of cancer. These approaches have had spectacular successes in some instances with limited successes in others because of lack of specificity or restricted anti-tumor effects associated with unacceptable immunologic reactions.

“From Sample to Assay – From R&D to IVD” was the title of a two-day workshop Scienion AG hosted in Berlin recently. Almost 100 participants from 12 countries benefited from an outstanding program.

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

The Company announces collaboration with Bayer Innovation GmbH for the development of a personalized Non-Hodgkin's-Lymphoma vaccine.

Marcus Evans, the producer of high-level business events for the world’s leading business decision-makers, has announced The Discovery Summit 2010, taking place from 19-21 September 2010 in Las Vegas, NV, USA.

Publication describes the use of RoboSep® to isolate CD4+ and CD8+ T cells.

Entry into Phase I marks a significant milestone for Genticel, which completed a EUR 13.1 million fund-raising in February 2010.

The acquisition gives Encorium capabilities to run clinical trials in South America, India and Asia Pacific.

Discovery to advance HIV vaccine design, antibody therapy for other diseases.

Using the HuALN technology AFFiRiS anticipates accelerating the progression of its human vaccine candidates into clinical trials.